OBJECTIVE: The primary endpoint in our study was to investigate the effect of a red yeast rice (RYR) product on plasma lipids. DESIGN: A randomized, double-blind, placebo controlled study was performed. Patients were randomized to either RYR (HypoCol, 4 capsules/day) (n=22) or placebo (n=20) for 16 weeks. Inclusion criteria were male or female, 18-75 years, LDL-cholesterol between 3.0 and 6.0 mmol/L, fasting triglyceride level less than 4.5 mmol/L. RESULTS: Patients receiving RYR experienced a significant reduction in LDL-cholesterol (23.0%) and total cholesterol (15.5%) compared to placebo after 16 weeks of treatment (p<0.001). CONCLUSION: The tested red yeast rice product demonstrated a significant cholesterol lowering effect compared to placebo, and was well tolerated in this Caucasian population.
RCT Entities:
OBJECTIVE: The primary endpoint in our study was to investigate the effect of a red yeastrice (RYR) product on plasma lipids. DESIGN: A randomized, double-blind, placebo controlled study was performed. Patients were randomized to either RYR (HypoCol, 4 capsules/day) (n=22) or placebo (n=20) for 16 weeks. Inclusion criteria were male or female, 18-75 years, LDL-cholesterol between 3.0 and 6.0 mmol/L, fasting triglyceride level less than 4.5 mmol/L. RESULTS:Patients receiving RYR experienced a significant reduction in LDL-cholesterol (23.0%) and total cholesterol (15.5%) compared to placebo after 16 weeks of treatment (p<0.001). CONCLUSION: The tested red yeastrice product demonstrated a significant cholesterol lowering effect compared to placebo, and was well tolerated in this Caucasian population.
Authors: Dirk W Lachenmeier; Yulia B Monakhova; Thomas Kuballa; Sigrid Löbell-Behrends; Sibylle Maixner; Matthias Kohl-Himmelseher; Asja Waldner; Christian Steffen Journal: Chin Med Date: 2012-03-22 Impact factor: 5.455
Authors: Veronique Verhoeven; Anastasia Van der Auwera; Luc Van Gaal; Roy Remmen; Sandra Apers; Michel Stalpaert; Johan Wens; Nina Hermans Journal: BMC Complement Altern Med Date: 2015-03-10 Impact factor: 3.659